Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 4, 2013, Pages 406-419

  Correia, Sónia C ^a,b   Santos, Renato X ^a,b   Santos, Maria S ^a,b   Casadesus, Gemma ^c   LaManna, Joseph C ^d   Perry, George ^c,e   Smith, Mark A ^c   Moreira, Paula I ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of San Antonio   (United States)

Author keywords

Cortex; Hippocampus; Intracerebroventricular injection of streptozotocin; Mitochondria; Oxidative stress and damage; Sporadic Alzheimer's disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN[1-42]; CALCIUM; CYTOCHROME C OXIDASE; GLUCOSE; HYDROGEN PEROXIDE; INSULIN; LIPID; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OXOGLUTARATE DEHYDROGENASE; PYRUVIC ACID; STREPTOZOCIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; BRAIN MITOCHONDRION; BRAIN WEIGHT; COGNITION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; REPOLARIZATION; RESPIRATION CONTROL; WISTAR RAT;

ADENINE NUCLEOTIDES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD GLUCOSE; BRAIN; DISEASE MODELS, ANIMAL; ESCAPE REACTION; GLUTATHIONE; GLUTATHIONE DISULFIDE; HYDROGEN PEROXIDE; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; OXYGEN CONSUMPTION; RATS; RATS, WISTAR; REACTION TIME; STREPTOZOCIN;

EID: 84878623135     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310040006     Document Type: Article

References (88)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 362(4): 329-44 (2010).
2. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 16(4):741-61 (2010).
3. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3(1):75-80 (2001).
4. Smith MA. Alzheimer disease. Int Rev Neurobiol 42: 1-54 (1998).
5. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev 10(2): 264-73 (2011).
6. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 541:135-52 (2004).
7. Hoyer S, Lannert H. Long-term abnormalities in brain glucose/ energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein. J Neural Transm Suppl 195-202 (2007).
8. Henneberg N, Hoyer S. Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? Arch Gerontol Geriatr 21(1): 63-74 (1995).
9. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109(3): 341-60 (2002).
10. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490(1-3):115-25 (2004).
11. Frolich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann NY Acad Sci 893: 290-3 (1999).
12. Benard G, Bellance N, James D, Parrone P, Fernandez H, Letellier T, et al. Mitochondrial bioenergetics and structural network organization. J Cell Sci 120(Pt 5): 838-48 (2007).
13. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58(4): 495-505 (2005).
14. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 60(5): 748-66 (2008).
15. Blass JP, Sheu RK, Gibson GE. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann NY Acad Sci 903: 204-21 (2000).
16. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57(5): 695-703 (2005).
17. Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101(3): 757-70 (2007).
18. Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl:217-33 (2007).
19. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 81: 527-42 (2001).
20. Noble EP, Wurtman RJ, Axelrod J. A simple and rapid method for injecting H3-norepinephrine into the lateral ventricle of the rat brain. Life Sci 6(3): 281-91 (1967).
21. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11(1): 47-60 (1984).
22. Moreira PI, Santos MS, Moreno A, Rego AC, Oliveira C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J Neurosci Res 69(2): 257-67 (2002).
23. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J Biol Chem 177(2): 751-66 (1949).
24. Estabrook RE. Mitochondrial respiratory control and the polarographic measurement of ADP/O ratios. Methods Enzymol 10: 41-7 (1967).
25. Kamo N, Muratsugu M, Hongoh R, Kobatake Y. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenyl phosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state. J Membr Biol 49(2): 105-21 (1979).
26. Jensen BD, Gunter. The use of tertaphenylphosphonium (TPP+) to measure membrane potentials in mitochondria: membrane binding and respiratory effects. Biophys J 45: 92 (1984).
27. Muratsugu M, Kamo N, Kurihara K, Kobatake Y. Selective electrode for dibenzyl dimethyl ammonium cation as indicator of the membrane potential in biological systems. Biochim Biophys Acta 464(3): 613-9 (1977).
28. Gohil K, Jones DA. A sensitive spectrophotometric assay for pyruvate dehydrogenase and oxoglutarate dehydrogenase complexes. Biosci Rep 3(1): 1-9 (1983).
29. Mastrogiacomo F, Bergeron C, Kish SJ. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem 61(6): 2007-14 (1993).
30. Moreira PI, Santos MS, Moreno AM, Proenca T, Seica R, Oliveira CR. Effect of streptozotocin-induced diabetes on rat brain mitochondria. J Neuroendocrinol 16(1): 32-8 (2004).
31. Barja G. Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. J Bioenerg Biomembr 31(4): 347-66 (1999).
32. Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN, Jr., Sunderman FW, Jr. Lipoperoxides in plasma as measured by liquidchromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem 33(2 Pt 1): 214-20 (1987).
33. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74(1): 214-26 (1976).
34. Du H, Yan SS. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta. Biochim Biophys Acta 1802(1): 198-204 (2010).
35. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 462(2): 245-53 (2007).
36. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113): 787-95 (2006).
37. Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 218(2): 286-92 (2009).
38. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem 109 (1):153-9 (2009).
39. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112(5): 1199-208 (1998).
40. DeCarli C. The role of neuroimaging in dementia. Clin Geriatr Med 17(2): 255-79 (2001).
41. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57(3): 339-44 (2000).
42. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 35(9-10): 1363-72 (2000).
43. Wallace DC. Mitochondrial DNA in aging and disease. Sci Am 277(2): 40-7 (1997).
44. Labak M, Foniok T, Kirk D, Rushforth D, Tomanek B, Jasiński A, Grieb P. Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. Acta Neurochir Suppl 106: 177-81 (2010).
45. Chagnon P, Betard C, Robitaille Y, Cholette A, Gauvreau D. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Neuroreport 6(5): 711-5 (1995).
46. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89(6): 1417-26 (2004).
47. Cassarino DS, Swerdlow RH, Parks JK, Parker WD, Jr., Bennett JP, Jr. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun 248(1): 168-73 (1998).
48. Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA, et al. Alzheimer's disease cybrids replicate betaamyloid abnormalities through cell death pathways. Ann Neurol 48(2): 148-55 (2000).
49. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP Jr, et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 49(4): 918-25 (1997).
50. Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, et al. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimers Dis 20(2): S535-50 (2010).
51. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30(10): 1574-86 (2009).
52. Salkovic-Petrisic M, Osmanovic-Barilar J, Bruckner MK, Hoyer S, Arendt T, Riederer P. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm 118(5): 765-72 (2011).
53. Meier-Ruge WA, Bertoni-Freddari C. Pathogenesis of decreased glucose turnover and oxidative phosphorylation in ischemic and trauma-induced dementia of the Alzheimer type. Ann NY Acad Sci 826: 229-41 (1997).
54. Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25(47): 10874-83 (2005).
55. Smith MA, Drew KL, Nunomura A, Takeda A, Hirai K, Zhu X, et al. Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem Int 40(6): 527-31 (2002).
56. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106:14670-5 (2009).
57. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 106: 20057-62 (2009).
58. Gibson GE, Park LC, Zhang H, Sorbi S, Calingasan NY. Oxidative stress and a key metabolic enzyme in Alzheimer brains, cultured cells, and an animal model of chronic oxidative deficits. Ann N Y Acad Sci 893: 79-94 (1999).
59. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 21(3): 455-62 (2000).
60. Imahori K. The biochemical study on the etiology of Alzheimer's disease. Proc Jpn Acad Ser B Phys Biol Sci 86(1): 54-61 (2010).
61. Ko LW, Sheu KF, Thaler HT, Markesbery WR, Blass JP. Selective loss of KGDHC-enriched neurons in Alzheimer temporal cortex: does mitochondrial variation contribute to selective vulnerability? J Mol Neurosci 17(3): 361-9 (2001).
62. Schapira AH. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr Opin Neurol 9(4): 260-4 (1996).
63. Tretter L, Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 20(24): 8972-9 (2000).
64. Gunter TE, Buntinas L, Sparagna G, Eliseev R, Gunter K. Mitochondrial calcium transport: mechanisms and functions. Cell Calcium 28(5-6): 285-96 (2000).
65. Rizzuto R, Bernardi P, Pozzan T. Mitochondria as all-round players of the calcium game. J Physiol 529 Pt 1: 37-47 (2000).
66. Territo PR, Mootha VK, French SA, Balaban RS. Ca(2+) activation of heart mitochondrial oxidative phosphorylation: role of the F(0)/F(1)-ATPase. Am J Physiol Cell Physiol 278(2): C423-35 (2000).
67. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 10(7): 481-94 (2009).
68. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 31(9): 454-63 (2008).
69. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3(11): 862-72 (2002).
70. Kumar U, Dunlop DM, Richardson JS. Mitochondria from Alzheimer's fibroblasts show decreased uptake of calcium and increased sensitivity to free radicals. Life Sci 54(24): 1855-60 (1994).
71. Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD, et al. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 17(12): 4612-22 (1997).
72. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14(10): 1097-105 (2008).
73. Du H, Guo L, Zhang W, Rydzewska M, Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol Aging 32(3): 398-406 (2011).
74. Brustovetsky N, Dubinsky JM. Limitations of cyclosporin A inhibition of the permeability transition in CNS mitochondria. J Neurosci 20(22): 8229-37 (2000).
75. Moreira PI, Santos MS, Moreno A, Oliveira C. Amyloid betapeptide promotes permeability transition pore in brain mitochondria. Biosci Rep 21(6): 789-800 (2001).
76. Moreira PI, Custodio JB, Oliveira CR, Santos MS. Hydroxytamoxifen protects against oxidative stress in brain mitochondria. Biochem Pharmacol 68(1): 195-204 (2004).
77. Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 33(10): 1372-9 (2002).
78. Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, et al. Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 31(1-3): 205-17 (2005).
79. Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res 5(7): 491-504 (2003).
80. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, J, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21(9): 3017-23 (2001).
81. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14(2): 45-53 (2008).
82. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology, 45(8): 1594-601 (1995).
83. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150(1): 40-4 (1998).
84. Palmer AM, Burns MA. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 645(1-2): 338-42 (1994).
85. Resende R, Moreira PI, Proenca T, Deshpande A, Busciglio J, Pereira C, et al. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med 44(12): 2051-7 (2008).
86. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006;27(2):262-9.
87. Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev 25(3): 335-58 (1997).
88. Gu M, Owen AD, Toffa SE, Cooper JM, Dexter DT, Jenner P, et al. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci. 158(1): 24-9 (1998).